Highlights
– In the multicenter nonrandomized PUMP‑2 phase II trial (Franssen et al., J Clin Oncol 2025), HAIP floxuridine combined with systemic gemcitabine–cisplatin produced a 1‑year overall survival (OS) of 80.0% (95% CI, 69.6%–91.9%) among patients with unresectable intrahepatic cholangiocarcinoma (iCCA) confined to the liver, significantly higher than a historical 47% control (P < .001).
– Median OS was 22.3 months (95% CI, 19.7–35.9 months); 3‑year OS was 31.5% (95% CI, 20.4%–48.6%). Objective partial response rate was 44% and disease control at 6 months was 84%.